SCHEMBL9923660

SCHEMBL9923660

COc1c(C(C)C)cc2c(c1O)[C@@]1(C(=O)O)CCCC(C)(C)[C@@H]1CC2

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 15/20 0.80
▸ BCL9 O00512 3/20 0.80
▸ CTNNB1 P35222 3/20 0.80
▸ ALDH1A1 P00352 2/20 0.80
▸ CYP3A4 P08684 2/20 0.80
▸ MAPT P10636 2/20 0.80
▸ HPGD P15428 2/20 0.80
▸ MEN1 O00255 1/20 0.80
▸ PTGES O14684 1/20 0.80
▸ CYP2C9 P11712 1/20 0.80
▸ PNLIP P16233 1/20 0.80
▸ ALOX12 P18054 1/20 0.80
▸ GSTO1 P78417 1/20 0.80
▸ KMT2A Q03164 1/20 0.80
▸ KDM4E B2RXH2 1/20 0.80
▸ USP2 O75604 1/20 0.80
▸ TP53 P04637 1/20 0.80
▸ MAPK1 P28482 1/20 0.80
▸ HSD17B10 Q99714 1/20 0.80
▸ TDP1 Q9NUW8 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29405917 1.00 FDPS (0.80) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL13309664 0.89 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL29390188 0.89 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL12590737 0.89 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL9923661 0.89 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Carnosic Acid SCHEMBL18290359 0.89 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
SCHEMBL30726729 0.82 FDPS (0.77) FDPSBCL9CTNNB1ALDH1A1CYP3A4
Methyl Carnosate SCHEMBL29426661 0.82 FDPS (1.00) FDPSBCL9CTNNB1ALDH1A1CYP3A4
SCHEMBL15031246 0.81 FDPS (0.76) FDPSBCL9CTNNB1ALDH1A1CYP3A4
SCHEMBL6658577 0.80 FDPS (0.80) FDPSBCL9CTNNB1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680147-B2 Compositions DSM IP ASSETS B.V. (NL) 2014-03-25 — — US disclosed
US-20120149766-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2012-06-14 — — US disclosed
US-20120149766-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2012-06-14 — — US disclosed
US-20100317728-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2010-12-16 — — US disclosed
US-20100317728-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DSM IP ASSETS B.V. (NL) 2010-12-16 — — US disclosed
US-20100056615-A1 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS DSM IP ASSETS B.V. (NL) 2010-03-04 — — US disclosed
US-20100056634-A1 NOVEL COMPOSITIONS DSM IP ASSETS B.V. (NL) 2010-03-04 — — US disclosed
US-20100056615-A1 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS DSM IP ASSETS B.V. (NL) 2010-03-04 — — US disclosed
US-20100056634-A1 NOVEL COMPOSITIONS DSM IP ASSETS B.V. (NL) 2010-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317728-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DRD2, DRD4, CYP11B2 FDPS 169/4885BCL9 3645/4885CTNNB1 3736/4885
US-20120149766-A1 DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES DRD2, DRD4, CYP11B2 FDPS 169/4885BCL9 3645/4885CTNNB1 3736/4885
US-20100056615-A1 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS TNF, VDR, CYP24A1 FDPS 56/4885BCL9 2980/4885CTNNB1 2064/4885
US-20100056634-A1 NOVEL COMPOSITIONS TNF, CCL11, HMGCR FDPS 347/4885BCL9 2683/4885CTNNB1 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback